Isogenic iPSC pairs: the distribution fee is published, the licence that decides commercialisation is not

The distribution fee for an isogenic iPSC line pair is published, itemised by tier, and modest. The licence that determines whether anything you make from that line can ever be sold is named in a remarks field on a catalogue record, priced by nobody, and follows the line into every derivative.

That asymmetry is the buying problem. It is possible to plan a purchase entirely from public information and still not know the cost of the thing that gates the outcome.

Coriell names the applicable limited use label licence on the line record itself, for GM23338 that licence is held by iPS Academia Japan. BPS Bioscience states the same requirement on its own cardiomyocyte product page: commercial use is not allowed and requires an appropriate licence from iPS Academia Japan. Commercial-tier pricing buys a tube on commercial terms. It does not grant rights to the underlying reprogramming patents. The organisations that are careful about this price the two things separately, and the ones that are careless discover the distinction late.

The published fee table

Three things fall out of that table that change how you should plan.

The tier multiplier varies by repository: 1.37 at one Coriell repository, 1.58 at another, and exactly 2.00 at RIKEN. Those are policy decisions, not pricing. Budgeting a commercial project at “roughly 1.5× the academic fee” will be wrong at RIKEN by a third.

RIKEN itemises the licence and the others do not. RIKEN charges a Clontech Laboratories licence fee of JPY 21,010 per cell line as a separate visible line item on the academic tier. That is the only place in this survey where a licence appears on a fee schedule as a number. It is a small number, and its value is not the amount, it is that RIKEN shows you the licence exists as a cost category at all.

Nobody publishes the licence that matters for commercialisation. The limited use label licence named on the Coriell record has no published price anywhere. If your project’s endpoint is a product, a service sold for consideration, or anything beyond internal research, the gating cost is a number you cannot obtain from any page and must negotiate.

The wider academic-versus-commercial pricing pattern across this market is in academic versus commercial pricing.

RIKEN’s definition of for-profit is broader than most buyers assume

Worth stating on its own because it catches people.

RIKEN’s definition of for-profit use includes non-profit research aimed at patent acquisition. A university laboratory that intends to file is, by that definition, doing for-profit research and falls on the JPY 126,280 tier rather than the JPY 63,140 one.

That is published policy, and a reasonable one. But it means the tier question is not “is my institution a company”, it is “what is this work for”. A translational academic group with an eye on filing should read the definition before selecting a tier, because selecting the wrong one is a compliance problem rather than a pricing error.

The same logic applies in reverse. If the work is genuinely publication-directed with no filing intent, the academic tier is correct and worth taking. Halving the fee across a ten-line panel is real money.

What an isogenic control is, and why one pair is not enough

An isogenic control is a line genetically identical to its comparator except at the edited locus. It is the difference between a claim about a variant and a claim about two people. The definitional detail is in isogenic control cell lines.

The purchasing consequence that follows is the one most often skipped: a single isogenic pair controls for genetic background but not for clonal idiosyncrasy.

Editing and cloning introduce variation that has nothing to do with the edit. Work in Scientific Reports demonstrates that wild-type heterogeneity itself contributes to clonal variability in genome-edited cells (PMC9616811). If your mutant clone and your corrected clone differ in a phenotype, one candidate explanation is the edit and another is that they are two different clones.

Published practice reflects this. A 2026 iScience study reports global transcriptional changes across multiple isogenic C9orf72 patient iPSC-derived neuron lines (PMC13217883), the plural is the design. Work on a PSEN2 isogenic series examining autophagy and amyloid beta production (PMC12726313) uses a series rather than a pair. APOE-isogenic work on energy metabolism in iPSC-derived neurons (PMC11274733) and isogenic CTBP1 mutant neuronal work (PMC12741082) are both built on matched comparison rather than cross-donor comparison.

The procurement translation: budget for more than one independent pair when the finding matters. At published Coriell academic fees that is roughly $2,374 for one pair and $4,748 for two, a real increase, and considerably cheaper than a result that does not replicate. Decide this before the purchase order, because adding a second pair later means adding it from a different order, possibly a different passage, possibly a different year.

Correction or introduction: which direction was the pair made

Two lines can both be described as an isogenic pair and have been built in opposite directions.

Correction. Start from a patient line carrying the variant and correct it to wild type. The mutant arm carries the patient’s full genomic background including any modifiers; the corrected arm is the artificial one.

Introduction. Start from a healthy line and introduce the variant. The wild-type arm is the natural one; the mutant arm is engineered onto a background that never carried the variant.

Neither is universally better and both are used in published work, but they support different claims. A corrected pair speaks to what the variant does in that patient’s background. An introduced pair speaks to what the variant does in isolation. If your paper’s claim is about the variant generally, an introduced pair in a well-characterised reference background is often the cleaner argument; if the claim is about patient biology, correction is.

Ask the bank which direction the pair was made in. It is a one-line question and it changes the interpretation of everything downstream.

The allelic series, and the knockout arm people leave out

If your question is whether a variant causes gain or loss of function, a mutant-versus-wild-type pair cannot answer it. You need a knockout arm.

The logic is simple: if the variant behaves like the knockout, it is a loss-of-function allele; if it behaves differently from both the knockout and the wild type, it is doing something else. Without the third arm you have a difference and an interpretation, not a mechanism.

Allelic series cost linearly in this market, each line is a separate distribution fee, so a three-arm design at Coriell academic fees is roughly $3,561 rather than $2,374. That is the honest price of a mechanistic claim, and it is worth stating in a grant application rather than discovering at the reviewer’s comment.

Where zygosity matters, the heterozygous arm is the one most often dropped for budget reasons, and dropping it removes any ability to say anything about dosage.

Multi-bank sourcing, and why it slows everything down

A single pair sometimes spans two banks, and this is where lead times go wrong.

Each bank has its own material transfer agreement, its own execution timeline, and its own institutional signature requirements. EBiSC’s structure helps here: a single EBiSC Access and Use Agreement covers lines from multiple distributors, which is a genuine administrative simplification across a bank holding healthy controls, diagnosed disease lines and isogenic sub-clones across more than 45 diseases from donors aged 0 to 89.

EBiSC also states plainly that it cannot guarantee batch-specific delivery. That is honest and it is a design constraint: if both arms of your comparison must come from the same batch, an inventory bank cannot promise it, and you should plan accordingly rather than assume.

Two practical rules:

• Start MTA execution before you have finalised the scientific design. The paperwork is the long pole, not the shipping. Two to six weeks including MTA execution is the realistic envelope, longer where the pair spans two banks.
• Order both arms together from the same bank where possible. Sourcing the mutant from one bank and the control from another doubles the paperwork and introduces two independent characterisation regimes into a comparison whose entire value is that the two arms are alike.

The disclosure that complicates the sale

Worth naming as a positive example. The Coriell record for GM23338 notes that the parent fibroblast expansion was mosaic for a translocation no longer present in the stem cell.

That is a disclosure which makes the line harder to sell, and it is on the public record anyway. It is exactly the kind of thing a buyer needs to know and exactly the kind of thing most suppliers would prefer not to volunteer. When you are evaluating a bank, the presence of inconvenient disclosures on the line record is evidence about the bank, not just about the line.

It also carries a direct instruction: read the full line record, including the remarks field, not just the price and the genotype. The remarks field is where the licence is named and where disclosures like this one live.

QC checklist

• Certificate of analysis per line, per bank, reviewed before you commit.
• Genotype confirmation at the edited locus, in both members of the pair, with the sequencing method and read depth stated.
• Off-target analysis performed and its scope, in silico prediction, exome, or whole genome. These are very different assurances and the word “screened” covers all three.
• Karyotype documentation and the passage at which it was performed.
• Passage frozen, as a number.
• Reprogramming method, which determines the patent landscape as well as the biology.
• Pluripotency characterisation battery as the bank publishes it.
• The full remarks field on the line record, read in its entirety, including any mosaicism, provenance or consent disclosure.
• Named limited use label licences applicable to the line, obtained in writing.
• Donor consent and use-restriction documentation, including any restriction on genomic analysis.
• Mycoplasma and sterility status per the bank’s release testing.
• Whether the two arms came from the same batch, and the bank’s position on guaranteeing it.

Specification checklist for an isogenic pair enquiry

• The named variant and its zygosity, precisely, using standard nomenclature.
• Direction of pair construction: correction from a patient line, or introduction into a healthy line.
• Number of independent pairs required, with a stated reason. One is a pilot; more than one is a result.
• Whether an allelic series or a knockout arm is required to separate gain from loss of function.
• Sequencing evidence required at the edited locus for both members.
• Off-target analysis scope required.
• Reprogramming method constraint, if your downstream licence position depends on it.
• Intended use, stated honestly, research, commercial, or patent-directed, for correct fee tier and MTA scoping. This is a compliance field, not a negotiating position.
• Named label licences, requested explicitly in the first email rather than after the first successful experiment.
• Whether both arms can be supplied from the same batch, and what the bank will commit to.
• MTA execution timeline and the signature authority required at your institution.
• Delivery of both arms together versus staged against separate lead times.

Where to go next

The datasheet, unit, lead time and QC scope, is at isogenic-and-disease-ipsc-lines. The conceptual definition is in isogenic control cell lines, the commercialisation question is in cell line licensing for commercial use, and the two-tier pricing pattern across the whole market is in academic versus commercial pricing. The bank and vendor landscape is in iPSC line suppliers.

How we can help

The fees on this page are public and you can order against them yourself. What is worth outsourcing is the licence question, identifying every named label licence attached to a line before you build a programme on it, and getting the licensor to state terms in writing while the project is still a proposal rather than a result.

Tell us the variant, the design including how many independent pairs and whether you need a knockout arm, and the honest intended use, and we will identify which banks hold what, flag where a pair spans two agreements, start the MTA clock early, and put the licence position in writing before anyone raises a purchase order.